Overexpression of Her-2 upregulates FoxM1 in gastric cancer.

作者: WEIWEI QI , XIAOXIAO LI , YONGCHUN ZHANG , RUYONG YAO , WENSHENG QIU

DOI: 10.3892/IJMM.2014.1732

关键词:

摘要: The transcription factor, forkhead box protein M1 (FoxM1), and the tyrosine kinase receptor, human epidermal growth factor receptor-2 (Her-2), are aberrantly expressed in a number of malignancies, closely associated with development cancer. However, their regulatory mechanisms involvement tumor have not been extensively investigated, particularly gastric In present study, we examined expression levels FoxM1 Her-2 samples from patients cancer, as well cancer cell lines. Their connection between them were also explored. We found that was markedly higher samples, while strong association at mRNA level. When regulated lines, changed accordingly. Following transfection vectors into luciferase activity promoter positively increased along concentration pcDNA3.1-Her-2. Her-2-siRNA inverted this variation, which further confirmed by treatment inhibitor, trastuzumab, revealing regulates level cells. Our results suggest important diagnostic markers for may be potential cellular target therapeutic intervention, cancers resistant to Her-2-targeted therapy.

参考文章(36)
Rita Nahta, Francisco J Esteva, HER2 therapy: Molecular mechanisms of trastuzumab resistance Breast Cancer Research. ,vol. 8, pp. 215- 215 ,(2006) , 10.1186/BCR1612
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
S. J. McKenzie, K. A. Desombre, B. S. Bast, D. R. Hollis, R. S. Whitaker, A. Berchuck, C. M. Boyer, R. C. Bast, Serum levels of HER-2neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer Cancer. ,vol. 71, pp. 3942- 3946 ,(1993) , 10.1002/1097-0142(19930615)71:12<3942::AID-CNCR2820711224>3.0.CO;2-3
Robert H. Costa, FoxM1 dances with mitosis. Nature Cell Biology. ,vol. 7, pp. 108- 110 ,(2005) , 10.1038/NCB0205-108
Agnieszka Halon, Piotr Donizy, Przemyslaw Biecek, Julia Rudno-Rudzinska, Wojciech Kielan, Rafal Matkowski, HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients The Scientific World Journal. ,vol. 2012, pp. 941259- 941259 ,(2012) , 10.1100/2012/941259
Senthil K. Radhakrishnan, Uppoor G. Bhat, Douglas E. Hughes, I-Ching Wang, Robert H. Costa, Andrei L. Gartel, Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Research. ,vol. 66, pp. 9731- 9735 ,(2006) , 10.1158/0008-5472.CAN-06-1576
Christina Yau, Yixin Wang, Yi Zhang, John A. Foekens, Christopher C. Benz, Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers Breast Cancer Research and Treatment. ,vol. 126, pp. 803- 810 ,(2011) , 10.1007/S10549-011-1345-1
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel, Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. ,vol. 52, pp. 797- 805 ,(2008) , 10.1111/J.1365-2559.2008.03028.X
Inken Wierstra, Jürgen Alves, FOXM1, a typical proliferation-associated transcription factor. Biological Chemistry. ,vol. 388, pp. 1257- 1274 ,(2007) , 10.1515/BC.2007.159
Kaoru Okada, Yoshiyuki Fujiwara, Tsuyoshi Takahashi, Yurika Nakamura, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Yukinori Kurokawa, Masaki Mori, Yuichiro Doki, Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Annals of Surgical Oncology. ,vol. 20, pp. 1035- 1043 ,(2013) , 10.1245/S10434-012-2680-0